As per the analysis, the European in vitro diagnostics market was estimated at USD 15.29 billion in 2022 and is likely to grow at a CAGR of 5.08% during 2023-2028 to reach USD 20.66 billion in 2028.
Companies profiled -
Below given is the list of key players mentioned in the report -
- Abbott Laboratories, Inc.
- Alere, Inc.
- Bio-Rad Laboratories, Inc.
- Cepheid, Inc.
- Hologic, Inc.
- OraSure Technologies
- Qiagen N.V.
- Quidel Corporation
- Roche Diagnostics
- Siemens Healthcare GmbH.
Market Dynamics
The market dynamics of the European In Vitro Diagnostics (IVD) market are influenced by various factors that drive its growth. Here are some key growth factors-
- Rising chronic and infectious diseases – The prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases in Europe is rising. The Organisation for Economic Co-operation and Development (OECD) states that cardiovascular diseases (CVD) are the leading cause of death in Europe, causing ~3.9 million deaths every year, which corresponds to 45% of all deaths. This rise is leading to an increased demand for IVDs to diagnose or monitor these diseases.
- Growth in geriatric population – The European Union (Europe. eu) states that the median age of the EU's population is increasing. In 2022, more than one-fifth (21.1 %) of the EU population was aged 65 and over. It is projected that there will be close to half a million centenarians in the EU-27 by 2050. Greying of Europeans leads to high chances of chronic diseases, which require regular monitoring, and thus demand more IVDs.
- Rise in the use of personalized medicines – Personalized medicine is the practice of tailoring medical treatment to the individual patient's genetic makeup. This is becoming increasingly important as scientists learn more about the genetic basis of diseases. IVDs are playing a key role in personalized medicine by providing doctors with information about the patient's genetic makeup.
- Rising RD expenditure to introduce new products – The surge in demand for in-vitro diagnostic tests has encouraged the market players to invest more in RD and develop innovative products. For instance, in April 2023, bioMérieux – a French multinational biotechnology giant, and JMI Laboratories (JMI) announced a six-year partnership to undertake collaborative projects to enhance the effectiveness of quick microbiology diagnostics, crucial in the fight against antimicrobial resistance (AMR).
- Technological advancements – Continuous advancements in technology have improved the performance, accuracy, and efficiency of diagnostic tests. The introduction of innovative techniques, such as molecular diagnostics, point-of-care testing, and artificial intelligence has expanded the range of diagnostic capabilities and accelerated the adoption of IVD tests. For instance, in June 2023, news stated that the incorporation of AI technology in oncology-based in vitro diagnostic (IVD) products is projected to revolutionize cancer diagnosis, enabling early detection, and improved patient outcomes.
Market evaluation -
The COVID-19 outbreak has adversely affected most of the end-use industries and is still spreading and taking major economies in its grip and has diminished the market conditions. Experts at Stratview Research stay in touch with the key players in the market to keep themselves updated with all the upcoming trends, challenges, market strategies which can be helpful for businesses to survive during this pandemic.
Based on the product type, the market is segmented as instruments, reagents, software, and services. The reagents segment is expected to hold the major share of the market during the forecast period owing to its high precision and accuracy in diagnosis. Furthermore, the Covid-19 pandemic has increased the demand for reagents. Also, an increase in the use of self-diagnosis tests and the number of RD activities is expected to drive market growth during the forecast period.
Based on the technique type, the market is segmented as immunology, hematology, clinical chemistry, molecular diagnostics, coagulation, microbiology, and others. The molecular diagnostics segment is anticipated to register high growth in the market owing to the increasing demand for molecular diagnosis in infectious diseases. Furthermore, the rapid rise in chronic diseases, as well as the increase in the number of genetic disorders, is expected to drive market growth during the forecast period.
Based on the application type, the market is segmented as infectious diseases, diabetes, oncology/cancer, cardiology, nephrology, autoimmune diseases, drug testing, and others. The infectious diseases application type segment is estimated to account for the major share of the market during the forecast period on account of the increasing number of infectious diseases such as HIV-AIDS, hepatitis, and Respiratory Syncytial Virus.
In terms of country, Germany is estimated to be the leading country in the market over the forecast period. The growth of the market is owing to the increasing prevalence of infectious diseases and the growing demand for rapid tests. Furthermore, the presence of various manufacturing companies is expected to fuel market growth over the forecast period. The UK is also expected to offer substantial growth opportunities during the forecast period.
About Stratview Research-
Stratview Research is a global business intelligence firm having a strong and experienced team of industry professionals and research analysts. It has a wide clientele across all the major industries worldwide. Stratview Research currently serves a broad spectrum of industries including but not limited to Energy Chemicals, Advanced Materials, Automotive, and Aerospace. At Stratview, our aim is to build long term relations with our clients through unparalleled service.
Connect with the team –
Call @: +1-313-307-4176
Mail @: [email protected]
